Clinical Trial Update: A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral Immunodeficiency [Phase 3]

View source ↗

Summary

Phase 3 study comparing IVIG-PEG to standard Gamunex-C in people with primary immunodeficiency; results completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunodeficiency

Drugs mentioned

• Gamunex-C (intravenous immunoglobulin (IVIG))
• Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG)

Snippet

Sponsor: Grifols Therapeutics LLC | Conditions: Primary Immunodeficiency | Phase 3 | Status: COMPLETED | Results posted: 2023-06-05